• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Proarrhythmic effects of antiarrhythmic drugs: evolving concepts.

作者信息

Morganroth J

机构信息

Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia.

出版信息

Am Heart J. 1992 Apr;123(4 Pt 2):1137-9. doi: 10.1016/0002-8703(92)91073-a.

DOI:10.1016/0002-8703(92)91073-a
PMID:1553883
Abstract

Although antiarrhythmic drugs are prescribed to reduce an arrhythmia, they may have the paradoxic effect of actually exacerbating that arrhythmia or causing new or more serious forms. This effect is known as "proarrhythmia." Proarrhythmic events may be segregated into those that occur "early" after therapy (within 30 days) and those that occur "late," after many months of therapy and manifesting as a fatal event (an increased risk of sudden cardiac death). The ability of the physician to predict drug proarrhythmia and its severity depends on the class of antiarrhythmic drug chosen, the type of ventricular arrhythmia to be treated, and the severity of the patient's underlying left ventricular dysfunction. Before the start of antiarrhythmic therapy, the physician must be able to quantitate the degree of proarrhythmic risk so that the benefit/risk ratio of such drug use can be determined.

摘要

相似文献

1
Proarrhythmic effects of antiarrhythmic drugs: evolving concepts.
Am Heart J. 1992 Apr;123(4 Pt 2):1137-9. doi: 10.1016/0002-8703(92)91073-a.
2
Early and late proarrhythmia from antiarrhythmic drug therapy.抗心律失常药物治疗引起的早期和晚期心律失常
Cardiovasc Drugs Ther. 1992 Feb;6(1):11-4. doi: 10.1007/BF00050910.
3
[Proarrhythmic effects of anti-arrhythmia agents].[抗心律失常药物的促心律失常作用]
Rev Med Interne. 1995;16(8):602-7. doi: 10.1016/0248-8663(96)80759-4.
4
[The pro-arrhythmic effects of anti-arrhythmia agents].[抗心律失常药物的促心律失常作用]
Z Kardiol. 1994;83 Suppl 5:75-85.
5
Proarrhythmic effects of antiarrhythmic drugs.
Med J Aust. 1990 Jul 2;153(1):37-47. doi: 10.5694/j.1326-5377.1990.tb125462.x.
6
Prevalence and characteristics of proarrhythmia from moricizine (Ethmozine).莫雷西嗪(乙吗噻嗪)所致心律失常的发生率及特征
Am J Cardiol. 1989 Jan 15;63(3):172-6. doi: 10.1016/0002-9149(89)90280-4.
7
Clinical types of proarrhythmic response to antiarrhythmic drugs.抗心律失常药物致心律失常反应的临床类型。
Am J Cardiol. 1987 Apr 30;59(11):2E-9E. doi: 10.1016/0002-9149(87)90195-0.
8
Drug-induced early and late proarrhythmia.药物诱导的早期和晚期心律失常。
Cardiol Clin. 1992 Aug;10(3):397-401.
9
Proarrhythmia: a paradoxic response to antiarrhythmic agents.致心律失常作用:抗心律失常药物的一种反常反应。
Pharmacotherapy. 1989;9(3):144-53. doi: 10.1002/j.1875-9114.1989.tb04120.x.
10
Proarrhythmic response to antiarrhythmic drug as a risk factor for sudden cardiac death in patients with ischemic heart disease.抗心律失常药物的致心律失常反应作为缺血性心脏病患者心脏性猝死的一个危险因素。
Pacing Clin Electrophysiol. 1991 Nov;14(11 Pt 2):1947-50. doi: 10.1111/j.1540-8159.1991.tb02795.x.

引用本文的文献

1
HBK-10, A Compound with α-Adrenolytic Properties, Showed Antiarrhythmic and Hypotensive Effects in Rats.具有α-肾上腺素能阻断特性的化合物HBK-10在大鼠中显示出抗心律失常和降压作用。
Pharmaceuticals (Basel). 2022 Oct 12;15(10):1256. doi: 10.3390/ph15101256.
2
Resuscitation Outcomes Consortium-Amiodarone, Lidocaine or Placebo Study (ROC-ALPS): Rationale and methodology behind an out-of-hospital cardiac arrest antiarrhythmic drug trial.复苏结局联合会-胺碘酮、利多卡因或安慰剂研究(ROC-ALPS):院外心脏骤停抗心律失常药物试验背后的原理和方法。
Am Heart J. 2014 May;167(5):653-9.e4. doi: 10.1016/j.ahj.2014.02.010. Epub 2014 Mar 1.
3
Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.
伊伐布雷定与氨氯地平治疗稳定型劳力性心绞痛患者的抗心绞痛疗效及安全性比较:一项为期3个月的随机、双盲、多中心、非劣效性试验
Drugs. 2007;67(3):393-405. doi: 10.2165/00003495-200767030-00005.